검색어: leukopaenia (영어 - 스웨덴어)

leukopaenia
trombocytopeni, lymfadenopati, lymfopeni vanlig: te

anaemia, leukopaenia
trombocytopeni

leukopaenia, anaemia, thrombocytopaenia
infektioner och infestationer

leukopaenia thrombocytopaenia, lymphadenopathy, lymphopenia
trombocytopeni, lymfadenopati, lymfopeni vanlig:

leukopaenia, anaemia, neutropaenia, thrombocytopaenia
leukopeni, anemi, neutropeni, trombocytopeni

leukopaenia thrombocytopaenia, lymphadenopathy, lymphopenia aplastic anaemia
trombocytopeni, lymfadenopati, lymfopeni vanlig:

eosinophilic disorders, leukopaenia (including neutropaenia, lymphopaenia)
eosinofila störningar, leukopeni (inklusive neutropeni, lymfopeni)

sepsis related to leukopaenia was observed infrequently (< 1%).
sepsis relaterad till leukopeni observerades mindre ofta (< 1 %).

very common: neutropaenia, anaemia, leukopaenia common: thrombocytopaenia
trombocytopeni

haematological disorders, in particular leukopaenia, thrombocytopaenia and clotting dysfunction, might be expected.
hematologiska förändringar, särskilt leukopeni, trombocytopeni och koagulationsstörningar kan väntas.

leukopaenia thrombocytopaenia, lymphadenopathy, lymphopenia aplastic anaemia pure red cell aplasia, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura
biverkningar faryngit *, virusinfektion * bronkit, sinuit, herpes simplex (resistens), rinit bakterieinfektion pneumoni§, sepsis leukopeni trombocytopeni, lymfadenopati, lymfopeni aplastisk anemi ren erytrocytaplasi, idiopatisk trombocytopenia purpura, trombotisk trombocytopenia purpura

leukopaenia is the most frequent undesirable effect experienced with caelyx in this population; neutropaenia, anaemia and thrombocytopaenia have been observed.
neutropeni, anemi och trombocytopeni har observerats.

the most commonly reported haematologic adverse drug reactions associated with dacogen treatment included febrile neutropaenia, thrombocytopaenia, neutropaenia, anaemia and leukopaenia.
de vanligaste rapporterade hematologiska biverkningarna förknippade med dacogen-behandling inkluderade febril neutropeni, trombocytopeni, neutropeni, anemi och leukopeni.

myelosuppression associated with anaemia, thrombocytopaenia, leukopaenia, and rarely febrile neutropaenia, has been reported in caelyx-treated patients.
myelosuppression associerad med anemi, trombocytopeni, leukopeni och i sällsynta fall febril neutropeni, har rapporterats hos patienter behandlade med caelyx.

severe bone marrow suppression (severe leukopaenia, neutropaenia, or thrombocytopaenia; see section 4.2, table 5).
svår benmärgssuppression (svår leukopeni, neutropeni eller trombocytopeni; se avsnitt 4.2, tabell 5).

during the post-marketing period prolonged cytopaenias (thrombocytopaenia, anaemia, neutropaenia and leukopaenia) and bone marrow failure have been reported.
efter introduktion av läkemedlet på marknaden har utdragna cytopenier (trombocytopeni, anemi, neutropeni och leukopeni) och benmärgssvikt rapporterats.

coagulopathy, leukopaenia, eosinophil count increased, platelet count decreased, platelet count increased, lymphocyte count decreased, white blood cell count increased, neutrophil count decreased
anemi, trombocytopeni, koagulopati, leukopeni, ökat antal eosinofiler, minskat antal blodplättar, ökat antal blodplättar, minskat antal lymfocyter, ökat antal vita blodkroppar, minskat antal neutrofiler

treatment should be discontinued in case of severe leukopaenia (< 1,200/mm3), severe neutropaenia (< 750/mm3) or severe thrombocytopaenia (< 70,000/mm3).
behandlingen ska avbrytas vid fall av svår leukopeni (< 1 200/mm3), svår neutropeni (< 750/mm3) eller svår trombocytopeni (< 70 000/mm3).